12:00 AM
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ocriplasmin regulatory update

FDA accepted and granted Priority Review to a BLA from ThromboGenics for ocriplasmin to treat symptomatic vitreomacular adhesion. The PDUFA date is Oct. 17. The agency's Dermatologic and Ophthalmic Drugs Advisory Committee will meet on...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >